News und Analysen

Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market. Its stock price is up 6.6% in that time, outpacing the 3.2%

Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market. Its stock price is up 6.6% in that time, outpacing the 3.2%

Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market. Its stock price is up 6.6% in that time, outpacing the 3.2%

Because investing is future-oriented, it is important that investors purchase businesses with ample growth potential in the years ahead. The best way to do this is to only consider investing in

Shares of SomaLogic (NASDAQ: SLGC) were up more than 11% as of Tuesday at 11:15 a.m. ET. The biotech company reported second-quarter earnings after the markets closed on Monday. The healthcare stock

Shares of SomaLogic (NASDAQ: SLGC) were up more than 11% as of Tuesday at 11:15 a.m. ET. The biotech company reported second-quarter earnings after the markets closed on Monday. The healthcare stock

Shares of SomaLogic (NASDAQ: SLGC) were up more than 11% as of Tuesday at 11:15 a.m. ET. The biotech company reported second-quarter earnings after the markets closed on Monday. The healthcare stock

When a company's revenue and earnings plunge, it's understandable if investors begin to worry about its dividend. Pfizer (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest

When a company's revenue and earnings plunge, it's understandable if investors begin to worry about its dividend. Pfizer (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest

If you are looking for reliable dividend stocks that can provide steady income and growth in any market condition, you might want to consider these two blue chip companies that have proven their

High-yield dividend stocks often deliver better-than-average returns for investors over the long term, thanks to the power of compounding. Not all high-yield dividend stocks are table-pounding buys

High-yield dividend stocks often deliver better-than-average returns for investors over the long term, thanks to the power of compounding. Not all high-yield dividend stocks are table-pounding buys

Income investors won't be happy with dividends that aren't sustainable. Instead, they want to own dividend stocks that they can depend on.

Three Motley Fool contributors identified stocks that

Shares of BioLife Solutions (NASDAQ: BLFS) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The healthcare company's

Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's

Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's

Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's

Investing becomes an easier process the moment that you shift from a trading mindset to an ownership approach. That transformation begins when you realize that behind every stock ticker, there's a

Investing becomes an easier process the moment that you shift from a trading mindset to an ownership approach. That transformation begins when you realize that behind every stock ticker, there's a

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

Dividend stocks can be great additions to anyone's portfolio, and it's even better to buy quality ones when they're down. While the market has roared back this year following a downturn in 2022, it

As conventional investment wisdom has it, it's best to buy low and sell high. However, that only works when you have solid reasons to believe a company's shares will bounce back meaningfully after a